Please login to the form below

Not currently logged in
Email:
Password:

Kymriah

This page shows the latest Kymriah news and features for those working in and with pharma, biotech and healthcare.

Novartis buys cancer specialist Endocyte for $2.1bn

It’s worth pointing out that buying Endocyte also gives Novartis an additional platform in CAR-T cancer immunotherapy to complement its current assets, including already-marketed therapy Kymriah (tisagenlecleucel) for ... Lutathera brought in $56m as

Latest news

More from news
Approximately 8 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    Early signs are looking good: Novartis’Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June ... Kymriah and Yescarta might

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    drugs, Novartis’Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’gene therapy Luxturna all reaching the market last year. ... US prices for Novartis’Kymriah and Gilead’s Yescarta are $475, 000 and $373, 000, respectively, for the

  • No incentive for a cure No incentive for a cure

    These include Kymriah, the pioneering CAR-T cell therapy from Novartis, which demonstrated a remarkable 83% remission rate in children and young adults with B-cell precursor acute lymphoblastic leukaemia. ... assessment found a price of $600, 000-750,

  • Health on instalment Health on instalment

    Cancer drugs Kymriah and Yescarta go for $475, 000 and $375, 000 respectively. ... Novartis is said to be open to a similar deal with Medicare for Kymriah.

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    Patients have a lot more power than they realise.”. Societal behaviour shifts can be slow and Novartis is keen to highlight its own initiatives such as the pricing of Kymriah, its

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest from PMHub

  • Training the next generation of biotech leaders

    In August, Novartis’ revolutionary CAR-T therapy, Kymriah, was approved. This was quickly followed by the approval of Kite’ s Yescarta in October. ... Kymriah, which make it into routine practice as a first-line treatment.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics